The Membranous Glomerulonephritis drugs in development market research report provides comprehensive information on the therapeutics under development for Membranous Glomerulonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Membranous Glomerulonephritis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Membranous Glomerulonephritis and features dormant and discontinued products.
GlobalData tracks 12 drugs in development for Membranous Glomerulonephritis by 12 companies/universities/institutes. The top development phase for Membranous Glomerulonephritis is phase ii with four drugs in that stage. The Membranous Glomerulonephritis pipeline has 11 drugs in development by companies and one by universities/ institutes. Some of the companies in the Membranous Glomerulonephritis pipeline products market are: Apellis Pharmaceuticals, NovelMed Therapeutics and Alpine Immune Sciences.
The key targets in the Membranous Glomerulonephritis pipeline products market include Cells Expressing ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1 (Cyclic ADP Ribose Hydrolase 1 or T10 or 2′ Phospho ADP Ribosyl Cyclase/2′ Phospho Cyclic ADP Ribose Transferase or ADP Ribosyl Cyclase 1 or CD38 or EC 3.2.2.6 or EC 2.4.99.20), Complement C3 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 1 or C3), and B Lymphocyte Antigen CD20 (B Lymphocyte Surface Antigen B1 or Bp35 or Leukocyte Surface Antigen Leu 16 or Membrane Spanning 4 Domains Subfamily A Member 1 or CD20 or MS4A1).
The key mechanisms of action in the Membranous Glomerulonephritis pipeline product include Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Agonist with one drug in Phase III. The Membranous Glomerulonephritis pipeline products include six routes of administration with the top ROA being Subcutaneous and six key molecule types in the Membranous Glomerulonephritis pipeline products market including Monoclonal Antibody, and Recombinant Protein.
Membranous Glomerulonephritis overview
Membranous Glomerulonephritis or membranous nephropathy is an autoimmune glomerular disease that affects the functioning of kidneys. Idiopathic and commonly seen in adults. It leads to nephrotic syndrome characterized by edema, proteinuria, frothy urine. Secondary causes of glomerulonephritis is NSAIDs induced, HBV, SLE, cancer and other infectious diseases. Edema, weight gain, fatigue, proteinuria are the symptoms and is diagnosed by analyzing protein levels in urine, biopsy of kidney, blood picture, GFR rate. Fluid restriction if edema is seen and low salt diet is recommended. If cause is autoimmune immunosuppressants are prescribed and antibiotics and angiotensin receptor blockers (ARBs) and anticoagulant therapy.
For a complete picture of Membranous Glomerulonephritis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
